Jasper Therapeutics, Inc. completed its acquisition of Kira Pharmaceuticals on 2026-07-16, according to the Form 8-K Jasper Therapeutics, Inc. filed with the SEC on 2026-07-17. The filing states a price of $132 million.
| Acquirer | Jasper Therapeutics, Inc. |
|---|---|
| Acquired | Kira Pharmaceuticals |
| Completed | 2026-07-16 |
| Price stated in the filing | $132 million |
| Reported by | Jasper Therapeutics, Inc. (JSPR), the buyer |
| Filing | Form 8-K, filed 2026-07-17 |
Want the whole picture on Jasper Therapeutics, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Jasper Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Jasper Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
1 cited source found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
What the filing says
On July 16, 2026, the Company completed its acquisition of Kira.
The price, in the filing's words
Pursuant to the Purchase Agreement, the Company agreed to sell an aggregate of approximately 4.7 million shares of Preferred Stock (the "PIPE Securities") for an aggregate cash purchase price of approximately $132 million (the "Financing").
More from the filing
- Completion of Acquisition or Disposition of Assets.
Agreement and Plan of Merger On July 16, 2026, Jasper Therapeutics, Inc., a Delaware corporation (the "Company" or "Jasper"), acquired Kira Pharmaceuticals ("Kira"), a Cayman Islands exempted company, in accordance with the terms of the Agreement and Plan of Merger, dated July 16, 2026 (the "Merger Agreement"), by and among the Company, Kira and Kira Holdco Inc., a Delaware corporation and a wholly owned subsidiary of the Company ("Merger Sub").
Pursuant to the Merger Agreement, Kira merged with and into Merger Sub, pursuant to which Merger Sub was the surviving corporation and became a wholly owned subsidiary of the Company (the "Merger").
Quoted from Jasper Therapeutics, Inc.'s Form 8-K.
This is the only completed acquisition Jasper Therapeutics, Inc. reported under Item 2.01 in the last twelve months.
Who runs it now, who owns it, where the money comes from and what to watch for, every claim linked to its source.
Order Full Report on Jasper Therapeutics, Inc.Look up Jasper Therapeutics, Inc. and see what is on record before you decide.
Get the free SnapshotWhere this comes from
A public company must file a current report on Form 8-K with the SEC within four business days of completing a significant acquisition or disposition of assets, under Item 2.01 of the report. The acquired company sometimes files one too, when the deal makes it a subsidiary of the buyer.
Every fact on this page is taken from one of those filings and linked to it: which company acquired which, the date the filing gives for completion, and the price when the filing states one in dollars, shown next to the sentence that states it. A filing states what was bought and on what terms; it rarely states why, and neither does this page.